⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923103 | 0.81 | EDNRB (0.35) | — | |
| SCHEMBL19923092 | 0.75 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL19923118 | 0.74 | ALDH1A1 (0.33) | — | |
| SCHEMBL19923211 | 0.69 | CCNC (0.38) | — | |
| SCHEMBL8676255 | 0.61 | ACHE (0.43) | — | |
| SCHEMBL19923138 | 0.60 | MAPK1 (0.37) | — | |
| SCHEMBL29435143 | 0.59 | ACHE (0.49) | — | |
| SCHEMBL119641 | 0.59 | ACHE (0.49) | — | |
| SCHEMBL6733945 | 0.59 | ACHE (0.49) | — | |
| SCHEMBL18095715 | 0.58 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |